Nothing said here yet.
to join the conversation.
| MCCOY JOHN A. JR.VICE PRESIDENT AND CONTROLLER | Sell | 27 | $3.0K | Wed, Sep 2 |
| Ford Robert BCHAIRMAN AND CEO | Sell | 218,535 | $25.3M | Tue, Aug 25 |
| Ford Robert BCHAIRMAN AND CEO | Sell | 180,297 | $20.9M | Tue, Aug 25 |
| Gilbert Cisneros | Buy | $8.0K | Fri, Sep 18 | Fri, Oct 9 |
| Pete Sessions | Sell | $75.0K | Fri, Oct 2 | Mon, Oct 5 |
| Richard W. Allen | Sell | $32.5K | Tue, Jul 14 | Mon, Aug 17 |
| Richard Dean Dr McCormick | Sell | $8.0K | Thu, Jul 30 | Wed, Aug 12 |
| Mike Kelly | Sell | $8.0K | Fri, Jul 17 | Wed, Aug 12 |
| Alan Armstrong | Sell | $32.5K | Fri, Mar 27 | Tue, Jul 21 |
| Rick Larsen | Sell | $8.0K | Wed, Jul 8 | Thu, Jul 9 |
| Richard Dean Dr McCormick | Buy | $16.0K | Fri, Jun 12 | Wed, Jul 8 |
| Gilbert Cisneros | Buy | $8.0K | Tue, Jun 16 | Thu, Jul 2 |
| Gilbert Cisneros | Sell | $8.0K | Fri, May 15 | Fri, Jun 5 |
| Julie Johnson | Sell | $8.0K | Tue, May 12 | Wed, Jun 3 |
| Josh Gottheimer | Sell | $8.0K | Wed, May 27 | Tue, Jun 2 |
Dexcom, known for its G-series of diabetes wearables, topped September-quarter expectations late Thursday, leading to a guidance hike.
Abbott Laboratories has seen a mixed share price record in recent years, which raises a straightforward question for anyone following the stock: Are the cash flows that Abbott can generate over time enough to justify where the shares trade today?
Boost ROI with home INR analyzers, recurring consumable sales, distribution partnerships, and local assembly to reduce tariff exposure and testing costs.Dublin, Oct.
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "South & Central America Point of Care Diagnostics Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis" has been added to ResearchAndMarkets.com's offering.
Abbott Laboratories (NYSE:ABT) plans to separate its Nutrition segment into an independent publicly traded company, targeting completion after regulatory and internal approvals.
Capitalize on Europe's aging population and chronic disease burden with specialized nutrition, channel-focused expansion and actionable country-level insightsDublin, Oct.
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.